Translate this page into:
Testicular Metastasis from Urothelial Carcinoma of the Renal Pelvis Detected on 18F-FDG PET/CT: A Rare Case
*Corresponding author: T Kishan Subudhi, Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India. kishansubudhi90@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Kannur S, Subudhi T, Parida GK, Ayyanar P, Agrawal K, Patro P. Testicular Metastasis from Urothelial Carcinoma of the Renal Pelvis Detected on 18F-FDG PET/CT: A Rare Case. Indian J Nucl Med. doi: 10.25259/IJNM_19_2026
Abstract
Renal pelvis carcinoma and renal cell carcinoma are known for their unpredictable metastatic behaviour. While lungs, liver, bones, and lymph nodes are common sites of spread, testicular metastasis is exceptionally rare. We report a 61-year-old male who presented with painless haematuria and was found to have a left renal pelvis mass with renal vein thrombus. Whole-body 18F- Fluorodeoxyglucose (FDG) PET/CT demonstrated extensive metastatic disease involving the lungs, liver, adrenal gland, multiple nodal groups, vertebrae, and an unusual FDG-avid right testicular mass. Ultrasound-guided biopsy of a liver lesion confirmed metastatic carcinoma, with immunohistochemistry favouring a urothelial origin. This case highlights the value of FDG PET/CT in the comprehensive staging of advanced renal malignancies and emphasises awareness of rare metastatic sites such as the testis, which may significantly impact staging, prognosis, and therapeutic decision-making.
Keywords
18F-FDG PET/CT
Renal pelvis carcinoma
Testicular metastasis
Urothelial carcinoma
INTRODUCTION
Upper tract urothelial carcinoma (UTUC), arising from the renal pelvis and ureter, is an uncommon but aggressive malignancy, accounting for approximately 5–10% of all urothelial tumours.[1] At presentation, a significant proportion of patients have locally advanced or metastatic diseases. The most frequent sites of metastasis include the lungs, liver, bones, and lymph nodes.[2] Testicular metastases from solid tumours are rare, constituting less than 1% of all testicular neoplasms, with prostate, lung, and gastrointestinal primaries being the most common sources.[3] Metastasis to the testicles from renal malignancies, including renal cell carcinoma and renal pelvis carcinoma, is exceptionally uncommon, with only isolated case reports and small series documented in the literature.[4,5] Proposed mechanisms include retrograde venous spread via the renal and gonadal veins, lymphatic dissemination, and arterial embolisation.[4] 18F-FDG PET/CT is increasingly used in advanced genitourinary malignancies for whole-body staging and detection of metastatic disease, particularly at atypical sites not routinely evaluated on conventional imaging.[6,7]We report a rare case of carcinoma of the renal pelvis with extensive multi-organ metastases, including testicular involvement, detected on 18F-FDG PET/CT.
CASE REPORT
A 61-year-old male presented with painless intermittent haematuria with passage of clots for one week. There was no associated fever, abdominal pain, or urinary retention. Past history was significant for right inguinal hernia repair performed 8–10 years earlier, with no available medical records. The patient reported chronic pan chewing with betel nut for approximately five years. There were no known comorbidities. He complained of disturbed sleep due to chronic back pain.
On examination, the patient was conscious, oriented, and hemodynamically stable. Abdominal examination was unremarkable. External genitalia appeared normal, and both testes were firm on palpation. Digital rectal examination revealed normal anal tone, intact bulbocavernosus reflex, and a Grade II firm prostate. Laboratory investigations revealed persistent microscopic and gross haematuria (up to 677 red blood cells per high-power field), pyuria, and elevated erythrocyte sedimentation rate (65 mm/hr). Renal and liver function tests were within normal limits. Echocardiography showed normal left ventricular systolic function with mild valvular regurgitation.
Ultrasonography of the kidneys, ureters, and bladder demonstrated a well-defined endophytic heteroechoic lesion measuring approximately 4.9 × 4.5 cm in the upper pole of the left kidney, suspicious for neoplasm. CT urography revealed a 6.0 × 6.5 × 6.4 cm ill-defined mass in the upper pole of the left kidney with enhancing septations and central hypo enhancement. Partial extension into the left renal vein with tumour thrombus was noted. Extensive retroperitoneal and pelvic lymphadenopathy with vascular encasement was present. Additional suspicious lesions were identified in the left adrenal gland and liver. MRI of the dorsal lumbar spine demonstrated L4–L5 disc bulge with canal stenosis and enlarged retroperitoneal lymph nodes.
The patient was referred to nuclear medicine for a whole body 18F-FDG PET/CT for staging workup. 18F-FDG PET/CT showed an FDG-avid, ill-defined mass with central necrosis in the left renal pelvis and extension into the left renal vein. It also showed retroperitoneal lymph nodes, bilateral lung nodules, a left adrenal lesion, liver, and L1 vertebral lesion, along with a right testicular mass [Fig 1].

Ultrasound-guided biopsy from a liver lesion revealed a malignant neoplasm arranged in nests and lobules, composed of tumour cells with clear-to-eosinophilic cytoplasm, moderate nuclear pleomorphism, and areas of necrosis. Mitotic activity was 16–18 per 10 high-power fields. On immunohistochemistry, tumour cells were positive for GATA3, p63, CK7, CK20, and moderately positive for AMACR, while negative for CD10 and CD117. PAX8 was non-contributory. The overall findings were consistent with metastatic carcinoma, favouring a urothelial origin in correlation with clinical and imaging findings [Figs 2 and 3]. A final diagnosis of metastatic carcinoma of the left renal pelvis with multi-organ involvement, including lungs, liver, adrenal gland, lymph nodes, vertebrae, and right testis was established.


DISCUSSION
UTUC and renal cell carcinoma differ in histogenesis but share overlapping metastatic patterns, most commonly involving lungs, liver, bones, and lymph nodes.[2] Testicular metastasis from renal malignancies is exceedingly rare, with only isolated case reports and small reviews described in the literature.[4,5] Several mechanisms have been proposed to explain testicular involvement, including retrograde venous spread through the renal and gonadal veins, lymphatic dissemination and arterial tumour embolisation.[4] The presence of renal vein tumour thrombus in the present case may have facilitated retrograde venous dissemination to the testis. FDG PET/CT plays a valuable role in the evaluation of advanced renal malignancies by enabling whole-body assessment and detection of metastatic disease at unusual sites.[6,7] Previous studies have demonstrated its usefulness in identifying atypical metastatic deposits that may not be suspected clinically or detected on conventional imaging.[6,7] In the present case, FDG PET/CT accurately delineated the full extent of disease, including rare testicular involvement, thereby providing crucial information for staging and therapeutic planning.
Learning points
Renal pelvis carcinoma can metastasise to rare sites, including the testis.
18F-FDG PET/CT allows comprehensive whole-body staging by detecting both common and atypical metastatic deposits.
Recognition of unusual metastatic patterns is critical for accurate staging and therapeutic decision-making.
CONCLUSION
This case illustrates a rare presentation of carcinoma of the renal pelvis with extensive metastatic disease, including testicular involvement. 18F-FDG PET/CT proved invaluable in delineating the full extent of disease and identifying unusual metastatic sites that may be overlooked on conventional imaging. Awareness of such atypical metastatic patterns is essential for accurate staging, prognostication, and optimal treatment planning in advanced renal malignancies.
Author contributions:
SK: Writing - original draft; TS: Conceptualisation, writing - review and editing, supervision; GKP: Validation, supervision; PA: Supervision, resources, investigation; KA: Conceptualisation; PP: Supervision
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given consent for their images and other clinical information to be reported in the journal. The patient understand that the patient’s names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The author confirms that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using the AI.
Financial support and sponsorship: Nil.
References
- EAU guidelines on upper urinary tract urothelial carcinoma. Eur Urol. 2018;73:111-22.
- [CrossRef] [PubMed] [Google Scholar]
- European Association of Urology guidelines on renal cell carcinoma. Eur Urol. 2022;82:399-410.
- [CrossRef] [PubMed] [Google Scholar]
- Metastatic carcinoma to the testis: A clinicopathologic analysis of 26 cases. Am J Surg Pathol. 2008;32:1683-93.
- [CrossRef] [PubMed] [Google Scholar]
- Testicular metastasis from renal cell carcinoma: A case report and review of the literature. Case Rep Oncol. 2017;10:388-91.
- [CrossRef] [PubMed] [Google Scholar]
- Testicular metastasis from renal cell carcinoma: A systematic review. J Clin Med. 2023;12:5636.
- [CrossRef] [PubMed] [Google Scholar]
- PET/CT in renal, bladder, and testicular cancer. PET Clin. 2015;10:147-66.
- [CrossRef] [PubMed] [Google Scholar]
- Meta-analysis of FDG PET and PET/CT in renal cell carcinoma. Eur J Radiol. 2012;81:345-51.
- [Google Scholar]

